Author

Xiaofeng Wang

Northeastern UniversityORCID 0000-0002-4184-0749Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Xiaofeng Wang4 papers · BGI Group (China)

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Chunge ZhongiD· 1 shared Dake XuiD· 1 shared Danni ZhangiD· 1 shared Fei TengiD· 1 shared Fengyun PeiiD· 1 shared Han ZhangiD· 1 shared Hua‐Jun WuiD· 1 shared Jing WangiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chunge ZhongORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CRISPR screens reveal convergent targeting strategies against evolutionarily distinct chemoresistance in cancer

Chunge Zhong, Wenjie Jiang, Yingjia Yao, Zexu Li, You Li, Shengnan Wang, Xiaofeng Wang, Wenjuan Zhu, Siqi Wu, Jing Wang, Shuangshuang Fan, Shixin Ma, Yeshu Liu, Han Zhang, Wenchang Zhao, , Fei Teng

This study identifies convergent therapeutic targets for chemoresistance in cancer using CRISPR screens across multiple drug conditions and cancer models.

Nature Communications · Jun 29, 2024Peer-reviewedCancer Biology